Skip to content
Trial Master File Reference Model
Trial Master File Reference Model

(a Community Group now part of CDISC)

Current version: TMF Reference Model V3.3

  • Home
  • About the Model
    • About the Model
    • CDISC TMF Reference Model Steering Committee
    • Intellectual Property Rights Policy
  • Community Exchange
    • FAQs
    • Forums
    • Resources
    • Exchange Mechanism
      • EMS News
      • EMS Roundtables
    • Resources Archive
  • Change Requests
  • Help
  • Login
  • Subscribe
Trial Master File Reference Model
Trial Master File Reference Model

(a Community Group now part of CDISC)

  • Home
  • About the Model
    • About the Model
    • CDISC TMF Reference Model Steering Committee
    • Intellectual Property Rights Policy
  • Community Exchange
    • FAQs
    • Forums
    • Resources
    • Exchange Mechanism
      • EMS News
      • EMS Roundtables
    • Resources Archive
  • Change Requests
  • Help
  • Login
  • Subscribe

Reply To: Auxiliary medicinal product

Home › Forums › Where do I file…. ? › Auxiliary medicinal product › Reply To: Auxiliary medicinal product

October 4, 2022 at 1:08 pm #4752
Meredith Lafond-Phesans
Participant

Hello,
we interpret Zone 06 to include any product administered as part of the study. This work in vaccines studies, but may be more complicated for drug studies?

I hope others will chime in to help!

Post navigation
Next Reply →

Recent Discussion Topics

  • PIA (=privacy impact assessment)
    2 weeks ago
  • Declaration of Interest
    3 weeks, 2 days ago
  • Is eTMF access control necessary for multiple CROs?
    2 weeks, 2 days ago

Relevant Links

  • TMF Reference Model Initiative Charter
  • Webinar – EU CTR & eTMF Impact
  • CDISC Affiliation Position Paper
  • TMF Reference Model v3.2.1
  • EDM Reference Model
  • eTMF Exchange Mechanism Standard Presentation
  • eTMF Exchange Mechanism Standard v1.0.2

Copyright © 2023 Trial Master File Reference Model | Powered by Astra WordPress Theme